For too long, people living with rare diseases have faced uncertainty, delays, and unacceptable variation in the care they receive. The launch of this quality standard is a watershed moment. For the ...

In 2025, we introduced a new collaborative Biosimilar Taskforce to address this potentially transformative area. The taskforce coordinates activity across the system , optimise biosimilar uptake and ...

NICE recommended rimegepant in 2023 for treating migraine and preventing episodic attacks (between 4 and 14 migraines per month), and atogepant in 2024 for preventing both episodic and chronic ...

More than 80,000 adults and teenagers across England suffering with a chronic skin condition could have their lives transformed after NICE today (Tuesday, 24 February) recommended the first licensed ...

People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...

Nice has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and progressive metabolic disorder, for routine use in the NHS in England.

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

A commercial access agreement was added to this guidance and the price list for tirzepatide was updated. Next review: This guidance will be reviewed if there is new evidence that is likely to change ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...